pd 98059 and 3-nitrotyrosine

pd 98059 has been researched along with 3-nitrotyrosine in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bramanti, P; Cuzzocrea, S; Di Paola, R; Galuppo, M; Mazzon, E; Paterniti, I	1
Cuzzocrea, S; Di Paola, R; Esposito, E; Galuppo, M; Impellizzeri, D; Mazzon, E; Paterniti, I	1

Other Studies

2 other study(ies) available for pd 98059 and 3-nitrotyrosine

Article	Year
PD98059, a specific MAP kinase inhibitor, attenuates multiple organ dysfunction syndrome/failure (MODS) induced by zymosan in mice. Pharmacological research, 2010, Volume: 61, Issue:2 Topics: Acute Disease; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Adhesion Molecules; Cytokines; Fas Ligand Protein; Flavonoids; I-kappa B Proteins; Inflammation Mediators; Male; Mice; Mitogen-Activated Protein Kinases; Multiple Organ Failure; Neutrophil Infiltration; NF-KappaB Inhibitor alpha; Nitric Oxide; Nitric Oxide Synthase Type II; p38 Mitogen-Activated Protein Kinases; Peritonitis; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Systemic Inflammatory Response Syndrome; Time Factors; Transcription Factor RelA; Tyrosine; Zymosan	2010
MEK inhibition suppresses the development of lung fibrosis in the bleomycin model. Naunyn-Schmiedeberg's archives of pharmacology, 2011, Volume: 384, Issue:1 Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Bleomycin; Body Weight; Butadienes; Fas Ligand Protein; Flavonoids; I-kappa B Proteins; Instillation, Drug; Interleukin-1beta; JNK Mitogen-Activated Protein Kinases; Lung; Male; MAP Kinase Kinase 1; Mice; Mice, Inbred Strains; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Neutrophils; NF-KappaB Inhibitor alpha; Nitric Oxide Synthase Type II; Nitriles; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pulmonary Edema; Pulmonary Fibrosis; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Tyrosine	2011

Article

Year

PD98059, a specific MAP kinase inhibitor, attenuates multiple organ dysfunction syndrome/failure (MODS) induced by zymosan in mice.

Pharmacological research, 2010, Volume: 61, Issue:2

Topics: Acute Disease; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Adhesion Molecules; Cytokines; Fas Ligand Protein; Flavonoids; I-kappa B Proteins; Inflammation Mediators; Male; Mice; Mitogen-Activated Protein Kinases; Multiple Organ Failure; Neutrophil Infiltration; NF-KappaB Inhibitor alpha; Nitric Oxide; Nitric Oxide Synthase Type II; p38 Mitogen-Activated Protein Kinases; Peritonitis; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Systemic Inflammatory Response Syndrome; Time Factors; Transcription Factor RelA; Tyrosine; Zymosan

2010

MEK inhibition suppresses the development of lung fibrosis in the bleomycin model.

Naunyn-Schmiedeberg's archives of pharmacology, 2011, Volume: 384, Issue:1

Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Bleomycin; Body Weight; Butadienes; Fas Ligand Protein; Flavonoids; I-kappa B Proteins; Instillation, Drug; Interleukin-1beta; JNK Mitogen-Activated Protein Kinases; Lung; Male; MAP Kinase Kinase 1; Mice; Mice, Inbred Strains; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Neutrophils; NF-KappaB Inhibitor alpha; Nitric Oxide Synthase Type II; Nitriles; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pulmonary Edema; Pulmonary Fibrosis; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Tyrosine

2011